SPX3,585.62-54.85 -1.51%
DIA287.30-4.91 -1.68%
IXIC10,575.62-161.89 -1.51%

BRIEF-Altimmune Announces Significant Reductions In Liver Fat Content And Body Weight In 12-Week Phase 1B Clinical Trial Of Pemvidutide In Subjects With NAFLD

BRIEF-Altimmune Announces Significant Reductions In Liver Fat Content And Body Weight In 12-Week Phase 1B Clinical Trial Of Pemvidutide In Subjects With NAFLD

Reuters · 09/14/2022 07:06
BRIEF-Altimmune Announces Significant Reductions In Liver Fat Content And Body Weight In 12-Week Phase 1B Clinical Trial Of Pemvidutide In Subjects With NAFLD

- Altimmune Inc ALT.O:

  • ALTIMMUNE ANNOUNCES SIGNIFICANT REDUCTIONS IN LIVER FAT CONTENT AND BODY WEIGHT IN 12-WEEK PHASE 1B CLINICAL TRIAL OF PEMVIDUTIDE IN SUBJECTS WITH NAFLD

  • ALTIMMUNE INC - ALL 3 PEMVIDUTIDE DOSING GROUPS (1.2 MG, 1.8 MG, 2.4 MG) ACHIEVED PRIMARY ENDPOINT

  • ALTIMMUNE INC - MEAN WEIGHT LOSS OF 4.9% (PLACEBO-ADJUSTED 4.7%) IN SUBJECTS WITHOUT DIABETES RECEIVING 1.8 MG DOSE AT 12 WEEKS OF TREATMENT

  • ALTIMMUNE INC - TRIAL ALSO MET ITS KEY SECONDARY ENDPOINT IN ALL PEMVIDUTIDE TREATMENT GROUPS

  • ALTIMMUNE INC - PEMVIDUTIDE WAS REPORTED TO BE GENERALLY WELL TOLERATED

Source text for Eikon: ID:

Further company coverage: ALT.O


((Reuters.Briefs@thomsonreuters.com;))